HN user

paviva

258 karma
Posts2
Comments79
View on HN

His French is so simple and yet, incredibly beautiful and elegant, in a way that I am not even able to express in words. Only Voltaire compares.

"tout le malheur des hommes vient d’une seule chose, qui est de ne savoir pas demeurer en repos, dans une chambre." -- "All the woe of man comes from one single thing only: not knowing how to remain at rest, in a room"

In the same text, he follows with:

"Le roi est environné de gens qui ne pensent qu’à divertir le roi, et à l’empêcher de penser à lui. Car il est malheureux, tout roi qu’il est, s’il y pense."

"The king is surrounded by people who think only of amusing the king and preventing him from thinking about himself. For he is unhappy, though he be king, if he thinks about it."

Most likely Gide ("Croyez ceux qui cherchent la vérité, doutez de ceux qui la trouvent", "Believe those who seek Truth, doubt those who find it") and not Voltaire ;)

Voltaire was generally more subtle: "un bon mot ne prouve rien", a witty saying proves nothing, as he'd say.

It is rare, and is probably due to a combination of green tea and weight loss. However, the effects are catastrophic, and it worth pointing out before someone decides to use tea extracts to "protect" their liver.

There are more cases that appears through cursory review of the literature, as most go unreported/unpublished. I have seen one case myself, and the person barely survived.

Pharma and rich greedy doctors are an easy target, but reality is (always) more complicated.

Pyridoxine/doxylamine is nothing new, and was released in the USA in the fifties, and withdrawn from the market in the early eighties due to numerous (baseless) lawsuit alleging it caused birth defects. This formulation is known as Diclectin in Canada, where there were no lawsuits (and thus, no withdrawal), and it costs pennies.

The medication was reintroduced in the USA about 10 years ago as Diclegis by another manufacturer, and Bonjesta is essentially Dicglesis with improved pharmacokinetics (whether this matters clinically is another question).

It is interesting to note that Bonjesta is produced by Duchesnay USA, which is owned by the Canadian company Duchesnay, which markets Diclectin here in Canada. I suspect that no American company is willing to risk a lawsuit *even* at the current seemingly absurdly high pricing. Duchesnay USA is essentially a mono-pill company, and I imagine that the strategy is that they're willing to go under in case of a class action.

Garbage statistics will not get better if you insist on some arbitrary fragility index threshold (and no accepted threshold of an "acceptable" fragility index does exist to the best of my knowledge). Also, using a lower alpha will automatically give you a larger sample size, without invoking a completely superfluous fragility index.

Nobody should interpret clinical studies in isolation; they only have meaning in a "qualitative" Bayesian framework which integrates physiological plausibility, other available trials, and risk/benefit ratio. The fragility index only muddies waters, as clinicians misinterpret it even more frequently than the much maligned p-value, all while not delivering any more information than the p-value itself.

There is no point.

The fragility index is essentially a repackaged p-value, and serves only to introduce even more confusion on the top of this already often misunderstood metric. See very good discussion here: https://academic.oup.com/eurheartj/article/38/5/346/2422087

Also, trials are generally designed to recruit the minimal number of patients we can get away with, and this is done for good reason (cost, feasibility, and the ethical concern of "using" the lowest possible number of human beings, while allowing any beneficial treatment to benefit the most as soon as possible). If someone's then pointing out that this trial is "fragile" -- well, yes, it was designed so in advance! Would you propose to expose 100 more patients to an inferior treatment just to improve your fragility index?

Probably significant. In this population of very severe patients, mortality was "only" 25% in patients managed without proning. Compare with mortalities around ~50% reported early into the pandemic in comparable populations.

Obviously difficult to say which part comes from patients presenting later in their disease course, doctors, nurses and respiratory therapists being overwhelmed with sudden influx of cases, and so forth -- and which can be directly attributed to premature and unwarranted intubation.

It is not known whether brain can be brought back at all once all signals stop.

This is incorrect. In a brain-dead patient, the isoelectric EEG serves to demonstrate the absence of brain activity despite adequate perfusion and absence of sedation, i.e, even though the computer is plugged in and you've pressed the start button, nothing happens, and thus, nothing is likely to happen in the future.

Isoelectric EEG can be induced with propofol and barbiturates, either voluntarily (refractory epilepsy) or involuntarily (anesthesia), without any obvious ill effects once the sedation is off.

PrEP is very likely cost-saving, i.e. it costs less than the life-long treatment of new HIV infections it will have prevented.

Unless you're willing to argue that treatment for HIV infections should not be covered, your argument against PrEP is pretty weak here.